<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704687</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0069</org_study_id>
    <nct_id>NCT04704687</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <acronym>STIMADHD</acronym>
  <official_title>Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU LYON</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Charles Perrens, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed&#xD;
      neurodevelopmental disorder in childhood. Patients with ADHD present inattention, impulsivity&#xD;
      and hyperactivity causing severe impairments on academic achievement, social and professional&#xD;
      life and daily functioning. Medications are effective in a majority of children with ADHD,&#xD;
      but about 30% do not respond or tolerate stimulants, and some parents refuse pharmacological&#xD;
      treatments.Transcranial Direct Current Stimulation is a safe and non-invasive technique of&#xD;
      brain stimulation used in several neurological and psychiatric disorders, and recently in&#xD;
      ADHD. In patients with ADHD, tDCS stimulations targeted frontal regions improve executive and&#xD;
      attentional functioning and daily life symptoms. The objective of this project is to evaluate&#xD;
      the efficacy of tDCS (vs sham) during cognitive-remediation exercises on ADHD symptoms&#xD;
      (inattention, impulsivity and hyperactivity as defined by DSM-5) in children with ADHD&#xD;
      between 7 and 14 years of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of ADHD-RS(ADHD Rating Scale-IV) between both arms</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis.&#xD;
How to Score&#xD;
For inattention (IA) subscale raw score: Add the odd-numbered items&#xD;
For hyperactivity-impulsivity (HI) subscale raw score: Add the even-numbered items&#xD;
To obtain the total raw score: Add the IA and Hi subscale raw scores&#xD;
Convert the raw scores to percentile scores by using the appropriate scoring profile provided on the back of the rating scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>Transcranial Direct Current Stimulation</condition>
  <arm_group>
    <arm_group_label>tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.</description>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_label>tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Children, male or females presenting a sufficient compliance for participate aged 7-14&#xD;
             years at the time of Visit 1 (Enrolment/baseline).&#xD;
&#xD;
          -  Children's parent or legally authorised representative must sign informed consent. The&#xD;
             children must sign assent if applicable (depending of age and understanding). The&#xD;
             principal investigator of the center where the child is included signs the document,&#xD;
             certifying that the family and the child, or their authorised representative, have&#xD;
             received informed consents.&#xD;
&#xD;
          -  Children meet DSM-5 criteria for ADHD (combined presentation) based on a clinical&#xD;
             evaluation using questionnaire ADHD-Rating-Scale (ADHD-RS) and the Kiddie Schedule for&#xD;
             Affective Disorders and Schizophrenia French version (Kiddie-SADS).&#xD;
&#xD;
          -  Subjects have a minimum ADHD-RS total score of 32 at Visit 1.&#xD;
&#xD;
          -  Children have a minimum CGI of 4 at Visit 1.&#xD;
&#xD;
          -  Children have an age-appropriate intellectual level evaluated with WISC-5 (Full IQ&#xD;
             &gt;80).&#xD;
&#xD;
          -  Children in which stimulant medication have been tested previously and stopped for&#xD;
             adverse effects could be included in the study after a wash out of at least seven&#xD;
             days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children have a neurological pathology or handicap: Epilepsy, cerebral palsy, sequelae&#xD;
             of brain injury (traumatic or ischemic or inflammatory...)&#xD;
&#xD;
          -  Children have a comorbid psychiatric disorder: conduct disorders, autism, severe&#xD;
             obsessive-compulsive disorder, mood disorder, bipolar illness, conduct disorder,&#xD;
             psychosis, and substance abuse.&#xD;
&#xD;
          -  Children under medication (stimulant or other psychotropic treatment, benzodiazepine,&#xD;
             antidepressant, hypnotics and melatonin) or who did not respond previously to&#xD;
             stimulant will not be included.&#xD;
&#xD;
          -  Severe sleep disorder.&#xD;
&#xD;
          -  Contraindication to tDCS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick BERQUIN, Pr</last_name>
    <phone>(33)3 22 08 76 70</phone>
    <email>berquin.patrick@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick BERQUIN, Pr</last_name>
      <phone>(33)3 22 08 76 70</phone>
      <email>berquin.patrick@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FOURNERET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel POULET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier BONNOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne SAUVAGET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel BOUVARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud JARDRI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent QUERNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

